Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Colorectal Neoplasms

  Free Subscription


1 Am J Surg
1 Ann Oncol
2 Anticancer Res
1 BMC Cancer
1 Br J Cancer
1 Cancer Lett
1 Clin Cancer Res
1 Dig Dis
2 Dis Colon Rectum
1 Eur J Cancer
2 Int J Cancer
1 J Pathol
1 J Surg Oncol
1 N Engl J Med
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Surg

  1. OSAGIEDE O, Spaulding AC, Frank RD, Merchea A, et al
    Predictors of palliative treatment in stage IV colorectal cancer.
    Am J Surg. 2018 Dec 14. pii: S0002-9610(18)30961.
    PubMed     Text format     Abstract available

    Ann Oncol

  2. VIVANCOS A, Elez E, Salazar R
    Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?
    Ann Oncol. 2018;29:532-534.
    PubMed     Text format    

    Anticancer Res

  3. KEARNEY MR, Chen EY, Vaccaro GM, Strother J, et al
    A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
    Anticancer Res. 2019;39:245-252.
    PubMed     Text format     Abstract available

  4. SHIMIZU D, Masuda T, Sato K, Tsuruda Y, et al
    CRMP5-associated GTPase (CRAG) Is a Candidate Driver Gene for Colorectal Cancer Carcinogenesis.
    Anticancer Res. 2019;39:99-106.
    PubMed     Text format     Abstract available

    BMC Cancer

  5. TIAN P, Zhu Y, Zhang C, Guo X, et al
    Ras-ERK1/2 signaling contributes to the development of colorectal cancer via regulating H3K9ac.
    BMC Cancer. 2018;18:1286.
    PubMed     Text format     Abstract available

    Br J Cancer

  6. PAEZ D, Tobena M, Fernandez-Plana J, Sebio A, et al
    Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Br J Cancer. 2018 Dec 26. pii: 10.1038/s41416-018-0348.
    PubMed     Text format     Abstract available

    Cancer Lett

  7. TAKEDA S, Shigeyasu K, Okugawa Y, Yoshida K, et al
    Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer.
    Cancer Lett. 2018 Dec 21. pii: S0304-3835(18)30724.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  8. WASSERMAN I, Lee LH, Ogino S, Marco MR, et al
    SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-1726.
    PubMed     Text format     Abstract available

    Dig Dis

  9. IWATSUBO T, Takeuchi Y, Yamasaki Y, Nakagawa K, et al
    Differences in Clinical Course of Intraprocedural and Delayed Perforation Caused by Endoscopic Submucosal Dissection for Colorectal Neoplasms: A Retrospective Study.
    Dig Dis. 2019;37:53-62.
    PubMed     Text format     Abstract available

    Dis Colon Rectum

    One Step Forward, Two Steps.
    Dis Colon Rectum. 2018;61:1339-1341.
    PubMed     Text format    

  11. HILL AG
    Epidurals and Colorectal Surgery: Have They Had Their Day?
    Dis Colon Rectum. 2018;61:1342-1343.
    PubMed     Text format    

    Eur J Cancer

  12. SCHWARTZ S, Szeto C, Tian Y, Cecchi F, et al
    Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Eur J Cancer. 2018;107:164-174.
    PubMed     Text format     Abstract available

    Int J Cancer

  13. WARD HA, Murphy N, Weiderpass E, Leitzmann MF, et al
    Gallstones and incident colorectal cancer in a large pan-European cohort study.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32090.
    PubMed     Text format     Abstract available

  14. VICENTINI M, Zorzi M, Bovo E, Mancuso P, et al
    Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer. Results from the IMPATTO study.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32089.
    PubMed     Text format     Abstract available

    J Pathol

  15. VALLE L, Vilar E, Tavtigian SV, Stoffel EM, et al
    Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine.
    J Pathol. 2018 Dec 25. doi: 10.1002/path.5229.
    PubMed     Text format     Abstract available

    J Surg Oncol

  16. LINO-SILVA LS, Guzman-Lopez JC, Zepeda-Najar C, Salcedo-Hernandez RA, et al
    Overall survival of patients with colon cancer and a prolonged time to surgery.
    J Surg Oncol. 2018 Dec 24. doi: 10.1002/jso.25354.
    PubMed     Text format     Abstract available

    N Engl J Med

  17. COEBERGH VAN DEN BRAAK RRJ, Martens JWM, Ijzermans JNM
    Correction to our Letter to the Editor about "CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer".
    N Engl J Med. 2018;379:2481.
    PubMed     Text format    

    PLoS One

  18. HAGMAN H, Bendahl PO, Lidfeldt J, Belting M, et al
    Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer.
    PLoS One. 2018;13:e0209838.
    PubMed     Text format     Abstract available

  19. LAW E, Levesque JV, Lambert S, Girgis A, et al
    The "sphere of care": A qualitative study of colorectal cancer patient and caregiver experiences of support within the cancer treatment setting.
    PLoS One. 2018;13:e0209436.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.